About
About Zhejiang Sunflower Great Health Limited Liability Company
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sales of anti-infective, cardiovascular, and digestive system drugs in China and internationally. It offers clarithromycin raw materials, an anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumonia, and urethritis and cervicitis; clarithromycin tablets; azithromycin dispersible tablets and injection for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis, and skin and soft tissue infection. The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, and acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for the treatment of hypertension; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal and gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.
Visit company website
5 years, 5 months ago
Zhejiang Sunflower Great Health Limited Liability Company is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.
From a valuation standpoint, the stock is 5.8% more expensive than other stocks from the Technology sector with a price to sales ratio of 8.5.
Zhejiang Sunflower Great Health Limited Liability Company's total revenue sank by 82.5% to $49M since the same quarter in the previous year.
Its net income has increased by 154.9% to $3M since the same quarter in the previous year.
Finally, its free cash flow grew by 152.6% to $10M since the same quarter in the previous year.
Based on the above factors, Zhejiang Sunflower Great Health Limited Liability Company gets an overall score of 2/5.